Printer Friendly

GENSIA TO PROCEED AS PLANNED WITH ARASINE REGULATORY FILINGS IN UNITED STATES AND EUROPE

 GENSIA TO PROCEED AS PLANNED WITH ARASINE REGULATORY FILINGS
 IN UNITED STATES AND EUROPE
 SAN DIEGO, Nov. 9 /PRNewswire/ -- Gensia Pharmaceuticals Inc. (NASDAQ: GNSA) today announced that, after meeting with regulatory authorities, the company plans to submit a New Drug Application (NDA) for Arasine(TM) to the U.S. Food and Drug Administration by the end of 1992 followed in January 1993 by a Marketing Authorization Application (MAA) in Europe under the Group "B" guidelines established by the Committee for Proprietary Medicinal Products (CPMP) of the European Community. As previously announced, Gensia plans to continue to evaluate Arasine in a new multicenter trial with patients undergoing coronary artery bypass surgery as additional support for the use of the drug in this indication.
 Gensia Pharmaceuticals is a San Diego-based biopharmaceutical company formed to discover, develop, manufacture and market novel pharmaceutical products for the treatment and diagnosis of human diseases.
 -0- 11/9/92
 /CONTACT: Martha L. Hough or Elizabeth A. Gard of Gensia Pharmaceuticals, 619-546-8300/
 (GNSA) CO: Gensia Pharmaceuticals Inc. ST: California IN: MTC SU:


JB-LS -- SD007 -- 8514 11/09/92 08:57 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 9, 1992
Words:183
Previous Article:PATRICK F. MCCARTAN TO SUCCEED RICHARD W. POGUE AS MANAGING PARTNER OF JONES, DAY, REAVIS & POGUE
Next Article:AUTOFACT '92 BRINGS NEWEST MANUFACTURING TECHNOLOGIES TO DETROIT
Topics:


Related Articles
GENSIA INITIATES PHASE 2 CLINICAL TRIAL WITH ARASINE IN NON-CARDIAC SURGERY
GENSIA ANNOUNCES COMPLETION OF ARASINE PHASE 3 TRIAL
GENSIA ANNOUNCES ARASINE CLINICAL RESULTS AND PLANS FOR REGULATORY SUBMISSIONS
ARBUTAMINE CLINICAL AND PRECLINICAL DATA ABSTRACTS PUBLISHED IN CIRCULATION
GENSIA FILES NDA FOR ARASINE AS PLANNED WITH THE U.S. FOOD AND DRUG ADMINISTRATION (FDA)
GENSIA FILES REGULATORY SUBMISSIONS FOR ARASINE AS PLANNED IN EUROPEAN MARKETS
GENSIA RETAINS EXCLUSIVE MARKETING RIGHTS TO ARASINE
GENSIA AND ARAMED INITIATE PHASE 1 WITH ARA COMPOUND
GENSIA LABORATORIES RECEIVES AADA APPROVAL FOR INJECTABLE DOXORUBICIN FIRST GENSIA APPROVAL FOR ONCOLYTIC PRODUCT IN A PLASTIC VIAL
GENSIA LABORATORIES RECEIVES ANDA APPROVAL FOR FLUPHENAZINE INJECTION

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters